Stay updated on Nivolumab in Relapsed/Refractory DLBCL Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Added revision tag v3.5.4 and removed v3.5.3. This indicates an internal version update rather than a change to study details.
    Difference
    0.0%
    Check dated 2026-05-17T10:09:46.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The page’s displayed software/API version indicator was updated from **v3.5.2** to **v3.5.3**, reflecting a general site release rather than any study detail change.
    Difference
    0.0%
    Check dated 2026-04-25T17:37:27.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-18T13:08:55.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    Updated the Italy location from Napoli to Naples (Naples, Italy, 80131) and added Naples, Italy, 80131 as a location. The page revision was updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-20T19:47:01.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Revision: v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-06T15:55:32.000Z thumbnail image
  8. Check
    97 days ago
    Change Detected
    Summary
    - Site revision updated from v3.4.1 to v3.4.2. No study content or user-facing details were changed.
    Difference
    0.0%
    Check dated 2026-02-12T15:22:37.000Z thumbnail image

Stay in the know with updates to Nivolumab in Relapsed/Refractory DLBCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.